Adare Pharma divests Adare Biome to dsm-firmenich

The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x

Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules

The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models

Granules India successfully completes Two US FDA Audits in a span of 2 weeks

The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.

Alembic Pharmaceuticals receives USFDA approvals for 5 products in Q1FY24

Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.

Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program

Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully

Granules India and Central Bureau of Narcotics unite to tackle drug abuse

Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society

Lilly's phase 2 retatrutide results show the investigational molecule achieved up to 17.5% mean weight reduction

Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program

Sun Pharma presents data from Phase 1 studies of GL0034

GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity

Natural Capsules announces strategic investment by Somerset Indus Capital Partners

Dr. Reddy's enters the trade generics business in India

Dr. Reddy's aims to roll out its trade generics across cities and towns in India